HRTX — Heron Therapeutics Share Price
0.000.00%
Last trade - 00:00- $527.29m
- $605.30m
- $127.04m
- 40
- 25
- 88
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.79% | ||
| Return on Equity | n/a | ||
| Operating Margin | -62.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 145.97 | 88.64 | 86.35 | 107.67 | 127.04 | 147.85 | 177.93 | 10.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Directors
- Barry Quart CHM (64)
- John Poyhonen PRE (61)
- David Szekeres COO (47)
- Kimberly Manhard EVP (61)
- Thomas Ottoboni SVP (62)
- Michael Mathews SVP (58)
- Lisa Peraza CAO (44)
- Sean Ristine VPR (51)
- John Arthur VPR (55)
- Christopher Storgard OTH (55)
- Craig Johnson LED (59)
- Stephen Davis IND (60)
- Sharmila Dissanaike IND
- Susan Rodriguez IND (57)
- Christian Waage IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 5th, 1987
- Public Since
- August 26th, 1987
- No. of Shareholders
- 88
- No. of Employees
- 126
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 150,653,158
- Address
- 4242 Campus Point Court, Suite 200, SAN DIEGO, 92121
- Web
- https://www.herontx.com/
- Phone
- +1 8582514400
- Auditors
- WithumSmith Brown PC
Upcoming Events for HRTX
Q3 2024 Heron Therapeutics Inc Earnings Release
Similar to HRTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Heron Therapeutics share price?
As of Today at 21:07 UTC, shares in Heron Therapeutics are trading at $3.23. This share price information is delayed by 15 minutes.
How has the Heron Therapeutics share price performed this year?
Shares in Heron Therapeutics last closed at $3.23 and the price had moved by +176.07% over the past 365 days. In terms of relative price strength the Heron Therapeutics share price has outperformed the S&P500 Index by +119.67% over the past year.
What are the analyst and broker recommendations for Heron Therapeutics?
The overall consensus recommendation for Heron Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Heron Therapeutics dividend yield?
Heron Therapeutics does not currently pay a dividend.
Does Heron Therapeutics pay a dividend?
Heron Therapeutics does not currently pay a dividend.
When does Heron Therapeutics next pay dividends?
Heron Therapeutics does not currently pay a dividend.
How do I buy Heron Therapeutics shares?
To buy shares in Heron Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Heron Therapeutics?
As of the previous close price of $3.23, shares in Heron Therapeutics had a market capitalisation of $486.61m.
Where are Heron Therapeutics shares listed?
Here are the trading details for Heron Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HRTX
What kind of share is Heron Therapeutics?
Based on an overall assessment of its quality, value and momentum Heron Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Heron Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Heron Therapeutics is $6.75. That is 108.98% above the last closing price of $3.23.
Analysts covering Heron Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.11 for the next financial year.
What is the trend in the Heron Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Heron Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +57.67%.
As of the last closing price of $3.23, shares in Heron Therapeutics were trading +53.63% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Heron Therapeutics PE Ratio?
The Heron Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Heron Therapeutics?
Heron Therapeutics' management team is headed by:
- Barry Quart - CHM
- John Poyhonen - PRE
- David Szekeres - COO
- Kimberly Manhard - EVP
- Thomas Ottoboni - SVP
- Michael Mathews - SVP
- Lisa Peraza - CAO
- Sean Ristine - VPR
- John Arthur - VPR
- Christopher Storgard - OTH
- Craig Johnson - LED
- Stephen Davis - IND
- Sharmila Dissanaike - IND
- Susan Rodriguez - IND
- Christian Waage - IND